Article in Function (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Malgorzata KasztanSection of Cardio Renal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Patrick A MolinaSection of Cardio Renal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Brandon M FoxSection of Cardio Renal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Elizabeth SaurageSection of Cardio Renal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Jackson C ColsonSection of Cardio Renal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
David M PollockSection of Cardio Renal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Jennifer S PollockSection of Cardio Renal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.ORCID 0000-0003-1956-0449
Funding
The Role of Endothelin-1 in Sickle Cell DiseaseU01HL117684 · NHLBI · AUGUSTA UNIVERSITY · PI KUTLAR, ABDULLAH, MEILER, STEFFEN · 2013 to 2017
$8.1M
Deep South KUH Premier Research - Interdisciplinary Mentored Education (PRIME) Training CoreTL1DK139566 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DAVID M POLLOCK · 2023 to 2026
$3.6M
Deep South KUH Premier Research- Interdisciplinary Mentored Education (PRIME) Networking CoreU2CDK133422 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DEAN GEORGE ASSIMOS, Orlando M Gutierrez · 2023 to 2026
$2.8M
Endothelin 1 in iron handling in sickle cell diseaseR01HL173038 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Malgorzata Kasztan · 2025 to 2026
$1.1M
Multi-parameter, analytic flow cytometerS10OD032296 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2022 to 2022
$464k
Novel Mechanisms of Decreased NO Bioavailability in Sickle Cell NephropathyF30DK107194 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FOX, BRANDON M · 2015 to 2018
$153k
Novel Endothelial and Immunologic Mechanisms of Pathophysiology in Sickle Cell DiseaseF31HL151264 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOLINA, PATRICK AXEL · 2019 to 2021
Sickle cell nephropathy (SCN) significantly shortens the life expectancy of patients with sickle cell disease (SCD). We previously reported that endothelin-1 (ET-1) and endothelin A receptor (ET
Indexed as
Anemia, Sickle CellEndothelin-1Kidney DiseasesAnimalsDisease Models, AnimalEndothelin A Receptor AntagonistsHumansKidneyMiceMice, KnockoutReceptor, Endothelin AT-LymphocytesEndothelin-1Endothelin A Receptor AntagonistsReceptor, Endothelin Aendothelinendothelin A receptornephropathysickle cell diseaseTH17 cell
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Endothelium-derived endothelin-1 mediates sickle cell nephropathy. · full record | OpenQuestion